Metabolite Biomarkers of Response (BoRs): Towards a fingerprint for the evolution of metastatic breast cancer.

Autor: Wolf J; Olaris, Inc, Waltham, MA, 02451, USA., Dong C; Olaris, Inc, Waltham, MA, 02451, USA., O'Day EM; Olaris, Inc, Waltham, MA, 02451, USA. Electronic address: eoday@olarisbor.com.
Jazyk: angličtina
Zdroj: Progress in biophysics and molecular biology [Prog Biophys Mol Biol] 2021 Oct; Vol. 165, pp. 8-18. Date of Electronic Publication: 2021 Aug 19.
DOI: 10.1016/j.pbiomolbio.2021.08.005
Abstrakt: Breast cancer is the most common cancer in women worldwide and despite improved treatment strategies, it persists as the second leading cause of death of women globally. Overall prognosis drops drastically once the cancer has metastasized, which is also associated with resistance to therapy. The evolution from a localized breast cancer to metastatic disease is complex and multifactorial. Metabolic reprogramming is a pre-requisite for this transition. In this graphical review, we provide an overview of altered metabolic pathways observed in metastatic breast cancer (mBC) and detail how metabolite biomarkers could serve as a novel class of precision medicine tools to improve the diagnosis, monitoring, and treatment of mBC.
Competing Interests: Declaration of competing interest The authors report this work was supported by Olaris, Inc. Josephine Wolf, Chen Dong and Elizabeth O'Day are employees at Olaris, Inc.
(Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: